Search

Objective: To investigate the expression of eight subunits of chaperonin containing t-complex 1 (CCT) in thyroid cancer (TC) tissues and their correlation with TC staging, patient prognosis, immune cell infiltration, immune checkpoint expression, and chemotherapy drug sensitivity. Methods: Data from The Cancer Genome Atlas (TCGA) database were used to analyze the expression of each CCT subunit in TC tissues and para-cancerous tissues as well as their relationship with the prognosis of TC patients. The biological function of each CCT subunit was analyzed by the Gene Set Enrichment Analysis (GSEA). Data from the TCGA and TIMER2.0 databases were used to analyze the correlations between the expression of each CCT subunit and the tumor microenvironment, infiltration of immune cells, chemotherapeutic drug sensitivity, and immune checkpoint expression. Results: Database analysis showed high mRNA expression of CCT3, CCT7, and CCT8 and low mRNA expression of CCT1, CCT2, CCT5, and CCT6B in TC tissues (P < 0.01 or P < 0.001). CCT3, CCT6B, and CCT8 mRNA expression were correlated with T staging (P < 0.05 or P < 0.01); CCT6B mRNA expression was associated with lymph node metastasis (P < 0.01); CCT5 mRNA expression was associated with distant metastasis (P < 0.05); and CCT6B may serve as an independent prognostic biomarker for overall survival (OS) in TC patients. CCT subunit expression was primarily enriched in signaling pathways such as graft rejection, complement, and interferongamma.Low expression groups of CCT subunits demonstrated significantly higher TC stromal score, immune infiltration score and composite score than the high expression groups (P < 0.05 or P < 0.01 or P < 0.001), displaying a negative correlation between the expression of each CCT subunit and TC stromal, immune infiltration and composite scores (all P < 0.01). The mRNA expression of each CCT subunit was positively correlated with CD8+ T cell and macrophage infiltration (all P < 0.05), the mRNA expression of most CCT subunits (except CCT6B and CCT7) was positively correlated with neutrophil infiltration (P < 0.05 or P < 0.01 or P < 0.001), whereas the mRNA expression of CCT3, 4, 7, and 8 was negatively correlated with CD4+ T-cell infiltration (all P < 0.05). Compared to the low-expression group, patients with high mRNA expression of most CCT subunit had significantly higher IC50 for chemotherapeutic agents such as sorafenib, levatinib, darafenib, trametinib, vandetanib, and cabozantinib (all P < 0.05 or P < 0.01 or P < 0.001). CCT subunit expression in TC tissues was significantly correlated with the expression of PD-1, PD-L1, PD-L2, CTLA4, CD80, and CD86 (P < 0.05 or P < 0.01 or P < 0.001). Conclusion: CCT complexes may promote TC development by affecting the tumor microenvironment thus impacting patient prognosis, potentially serving as a target for the diagnosis and immunotherapy of refractory TC. [ABSTRACT FROM AUTHOR]

Objective: To investigate the expression of structural maintenance of chromosome 4 (SMC4) in breast cancer and its prognostic value. Methods: The expression of SMC4 gene in breast cancer tissues and its correlation with the clinicopathological characteristics of patients were analyzed using the TIMER, GEPIA, UALCAN and GEO databases. The expression of SMC4 protein in breast cancer and adjacent normal tissues was detected using immunohistochemical (IHC) staining. Correlations between SMC4 expression and clinicopathological features of breast cancer were evaluated. The relationship between SMC4 expression and survival of patients with breast cancer was evaluated by Kaplan-Meier, GEPIA database, Cox proportional hazards regression model. Results: Bioinformatics analysis showed that the mRNA level of SMC4 in breast cancer tissues was significantly higher than that in normal adjacent tissues (P < 0.01), and was closely related to clinical stage, lymph node metastasis and chemotherapy resistance (all P < 0.05). IHC staining showed that the positive and strong positive rates of SMC4 in breast cancer tissues were significantly higher than those in normal adjacent tissues (all P < 0.05). The high protein expression of SMC4 was closely related to the age, clinical stage and lymph node metastasis of breast cancer patients (all P < 0.05). The cumulative survival rate of patients in SMC4 low expression group was significantly higher than that in the SMC4 high expression group, especially in patients with HER2+ breast cancer (P < 0.05). Additionally, SMC4 is an independent risk factor for prognosis in patients with breast cancer. Conclusion: SMC4 is highly expressed in breast cancer tissues. High SMC4 expression is closely related to lymph node metastasis, clinical stage, and prognosis of patients with breast cancer, making it a potential marker for the diagnosis and prognosis of breast cancer. [ABSTRACT FROM AUTHOR]

Glioma is the most malignant brain tumor with high mortality. Due to its complex biological characteristics such as malignant proliferation, invasion, drug resistance, and immunosuppression, the clinical treatment faces great difficulties. Although the survival rate has improved under surgery combined with radiotherapy and chemotherapy, the overall curative effect is still not obvious. As a kind of non coding RNA (ncRNA), microRNA (miRNA) which has been extensively studied in recent years is involved in the regulation of biological processes of normal tissues and various tumors (including glioma) in human. As a cancer suppressor gene, miRNA - 145 plays a regulatory role in the progression of glioma through a variety of pathways, especially as a targeted drug transported to the tumor area through nanocarriers to treat tumors, becoming a current research hotspot. This article summarizes the role of miRNA - 145 in pathological grading, tumor microenvironment, the regulation of glioma stem cells, drug resistance, and the prognosis of glioma, aiming to provide the reference for the diagnosis and treatment of glioma. [ABSTRACT FROM AUTHOR]

Pediatric - type low - grade glioma (pLGG) is the most common central nervous system tumor in children, and most pLGG exhibits non -invasive clinical behavior with a good prognosis. Total surgical resection is an important prognostic factor, and patients can achieve long-term survival after total tumor resection. However, tumors in deep location such as brain stem and optic pathway cannot be completely removed by surgery. Chemotherapy is the first choice of adjuvant treatment when the clinical symptoms of pLGG worsen or imaging progress. In recent years, in addition to traditional chemotherapy, the development and application of targeted therapy drugs have also made great progress. This article reviews the research progress and challenges of chemotherapy and targeted therapy of pLGG, in order to provide guidance for clinical practice. [ABSTRACT FROM AUTHOR]

Copyright of Journal of Clinical Nursing in Practice is the property of Journal of Clinical Nursing in Practice (Editorial Board, Shanghai Jiao Tong University Press) and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Objective: To verify whether phosphoglycerate mutase 1 (PGAM1) allosteric inhibitor could enhance the sensitivity of colon cancer cells to oxaliplatin (OXA). Methods: OXA sensitivity and PGAM1 expression levels of four consensus molecular subgroups (CMS) of colon cancer cells were analyzed according to genomics of drug sensitivity in cancer (GDSC）and cancer cell line encyclopedia (CCLE) databases. CCK8 assay and Annexin V/PI staining were used to investigate the effect of PGAM1 allosteric inhibitor HKB99 on the proliferation and apoptosis of human colon cancer cell lines. CCK8 assay were performed to investigate the effect of HKB99 combined with OXA on the proliferation of colon cancer DLD-1 cells and cooperativity index was analyzed according to the result. Results: Firstly, GDSC and CCLE databases results showed that CMS1 and CMS4 colon cancer cells were less sensitive to OXA than CMS2 and CMS3 cells in terms of the sensitive cells proportion. Compared with, the expression of PGAM1 was higher in CMS1 and CMS4 cells than in CMS1 and CMS3 cells (P＜0. 05). HKB99 significantly inhibits the proliferation of SW480, SCUN2B and DLD-1 cells, with an IC50 of approximately 1μM. Annexin V/PI staining results showed that apoptosis of DLD-1 cells was significantly increased compared with Control group after HKB99 treatment (P＜0. 01). Results of CCK8 assay result showed that 1. 5μM HKB99 significantly enhanced the inhibitory effect of OXA on colon cancer DLD-1 cells compared with control group (IC50: 0. 37 vs 3. 26μM). The cooperativity index analysis result showed that the synergistic coefficient of OXA with HKB99 was less than 1 at the concentration between 1. 56μM and 25μM. Conclusions: In this study, we found that CMS1 and CMS4 colon cancer cells are less sensitive to OXA and higher level of PGAM1compared with CMS2 and CMS3 cells. An allosteric inhibitor of PGAM1, HKB99, enhances the sensitivity of colon cancer cells to OXA, which suggests that HKB99 may enhance the sensitivity of OXA chemotherapy and provide a potential treatment strategy for patients with individualized chemotherapy in colon cancer. [ABSTRACT FROM AUTHOR]

The current focus of materials science and biomedical science research lies in two-dimensional (2D) MXenes materials, which possess an array of distinctive material attributes. These include superior optical characteristics, a high specific surface area, remarkable hydrophilicity, facile surface functionalization modification and impressive electrochemical properties. These features endow MXenes with vast application potential across multiple domains, particularly in the biomedical realm where advancements in tumor diagnosis and therapy have garnered significant research interest. These advancements primarily center on the enhancement of imaging technology and treatment methodologies. Notably, MXenes exhibit an array of unique physical and chemical properties, including remarkable fluorescence quenching capabilities, superior X-ray attenuation performance and highly efficient photothermal conversion. In the realm of diagnostic technologies, MXenes materials have emerged as a promising candidate for multimodal imaging, encompassing fluorescence imaging, photoacoustic imaging, computed tomography and magnetic resonance imaging (MRI). These materials, through their composite design, offer the potential to transcend the limitations of single-mode diagnostic techniques, thereby fostering innovative approaches in tumor imaging. Furthermore, MXenes exhibit exceptional characteristics as combination therapy materials, particularly in targeted drug delivery and optical therapy for tumor treatment. By harnessing the diverse physical and chemical properties of MXenes, personalized treatment strategies can be realized through precise drug delivery, thereby mitigating the toxic side effects associated with systemic chemotherapy. Currently, a pressing challenge in cancer research lies in the rational design and modification of MXenes probes that possess both diagnostic and therapeutic capabilities. This article aimed to provide a comprehensive review of the latest advancements, opportunities and challenges associated with two-dimensional MXenes materials and their derivatives in the context of tumor diagnosis and treatment. Additionally, it delved into the material synthesis, surface modification and tumor imaging research conducted in this field. Furthermore, it examined the obstacles and limitations encountered in the utilization of MXenes in the present context. The research and development of MXenes materials were integral to nanotherapy, and their novel properties, biological effects and oncological application value were thoroughly analyzed, in order to offer more effective and safer therapeutic options for cancer patients. [ABSTRACT FROM AUTHOR]

Background and objective Lung cancer is the cancer with the highest incidence and mortality rates in China, and non-small cell lung cancer (NSCLC) accounts for 80%-85% of all malignant lung tumors. Currently, surgical treatment remains the primary treatment modality for lung cancer. In recent years, the effectiveness of immune checkpoint inhibitors for NSCLC has become a consensus, and neoadjuvant immunochemotherapy (nICT) has shown promising efficacy and safety in early to intermediate stage NSCLC. However, there are fewer studies related to nICT for locally advanced NSCLC. This study aims to evaluate the efficacy and safety of nICT therapy in locally advanced resectable NSCLC. Methods 85 confirmed resectable stage IIIA and IIIB patients treated in the Department of Thoracic Surgery, Second Hospital of Lanzhou University, from January 2021 to April 2024, were divided into the nICT group (n=32) and the surgery alone group (n=53). Clinical baseline data, perioperative indicators, postoperative complications, imaging response rate, pathological response rate, incidence of adverse events, and quality of life were compared between the two groups. Results There were no statistically significant differences in clinical baseline data between the two groups (P>0.05). Incidence of choosing thoracotomy was higher in the nICT group than in the surgery alone group (P=0.002). There were no significant differences in surgical time, intraoperative blood loss, number of dissected lymph nodes, duration of chest tube placement, postoperative hospital stay, and R0 resection rate between the two groups (P>0.05). The overall incidence of postoperative complications was 31.25% in the nICT group and 22.64% in the surgery alone group, with no statistically significant difference (P=0.380). In the nICT group, the objective response rate (ORR) was 84.38%, with 5 cases of complete response (CR)(15.63%), 22 cases of partial response (PR)(68.75%), 15 cases of pathological response rate (pCR)(46.88%), and 11 cases of major pathological reaponse (MPR) (34.38%). During nICT treatment, 12 cases (37.50%) experienced grade 3 treatment-related adverse events, no death induced by adverse events or immune related adverse events. Moreover, the symptoms of the patients were improved after nICT treatment. Conclusion Neoadjuvant immunochemotherapy shows promising efficacy in locally advanced resectable NSCLC, with manageable treatment-related adverse events. It is a safe and feasible neoadjuvant treatment modality for locally advanced resectable NSCLC. [ABSTRACT FROM AUTHOR]

Copyright of Journal of Clinical Nursing in Practice is the property of Journal of Clinical Nursing in Practice (Editorial Board, Shanghai Jiao Tong University Press) and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Copyright of Chinese Journal of Cancer Biotherapy is the property of Editorial Office of Chinese Journal of Cancer Biotherapy and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Background and purpose: The plasma used for routine coagulation test (CCT) can only reflect a single component at a certain coagulation time point/segment, while thromboelastography (TEG) can depict the overall dynamic process curve of coagulation and fibrinolysis, which can more independently and completely reflect the true state of the blood and can serve as a supplement to coagulation function testing. This study aimed to evaluate the application value of combined coagulation function indexes in monitoring the hypercoagulable state of patients with colorectal cancer after chemotherapy, and to explore the risk factors of thrombosis in patients with colorectal cancer after chemotherapy, so as to provide reference for clinical monitoring of hypercoagulable state. Methods: A total of 160 patients with colorectal cancer from Fudan University Shanghai Cancer Center from June 2021 to June 2023 were selected as the experimental group, and 80 healthy subjects were selected as the control group. Then the experimental group was divided into a group without thrombosis (82 cases) and a group with thrombosis (78 cases) according to whether they had thrombosis or not. The determinations of thromboelastography (TEG) [coagulation reaction time (R), coagulation formation time (K), blood clot formation rate (a-Angle), maximum amplitude (MA) and coagulation index (CI)], conventional coagulation tests (CCT) [activated partial thromboplastin time (APTT), prothrombin time (PT), thrombin time (TT), fibrinogen (Fib), D-dimer (DD), fibrinogen degradation products (FDP)] and platelet count (PLT) were studied among three groups. With or without thrombosis as the criterion of hypercoagulable state, statistically significant indicators were selected to be included in the binary logistic regression analysis, and the receiver operating characteristic (ROC) curve was drawn to analyze the diagnostic efficacy of single and combined detection of the coagulation function indicators for hypercoagulable state in patients with colorectal cancer after chemotherapy. Basic information, tumor stage and Autar score of deep vein thrombosis were collected in 160 patients with colorectal cancer. Logistic regression analysis was performed to explore the risk factors of thrombosis. This study was approved by the Ethics Committee of Fudan University Shanghai Cancer Center (number: 050432-4-2108*). Results: Compared with the control group, the R, TT and PLT of the group with thrombosis were decreased (P<0.05), while APTT, PT, DD and FDP were increased (P <0.05). The differences in various indicators between the group with thrombosis and the control group were statistically significant (P<0.05). Compared with the group without thrombosis, the K in the group with thrombosis decreased (P<0.05), while Angle, MA, CI, FIB, DD and FDP all increased (P<0.05). ROC curve analysis showed that in the assessment of hypercoagulable state in patients with colorectal cancer after chemotherapy, the area under curve (AUC) of TEG was 0.756, sensitivity was 67.5%, and specificity was 73.8%. The AUC of CCT was 0.691, sensitivity was 78.8%, and specificity was 56.2%. The combined detection AUC was 0.840, sensitivity was 80.0%, and specificity was 77.5%. In the analysis of risk factors, tumor stage, distant metastasis and Autar score were correlated with thrombus formation in patients with colorectal cancer after chemotherapy (P<0.05), and the differences of the three risk factors in K, Angle, MA, CI, Fib, DD and FDP were statistically significant (P<0.05). Conclusion: K, Angle, MA, CI, Fib, DD and FDP are the main indicators to reflect the hypercoagulable state, and the combined detection of TEG and CCT can better reflect the coagulation state of patients with colorectal cancer after chemotherapy. Tumor stage H to IV, distant metastasis and high Autar score are risk factors for thrombosis. The incidence of thrombosis can be reduced by monitoring the relevant coagulation indicators in the high-risk population. [ABSTRACT FROM AUTHOR]

Objective To analyze the relationship between stress resistance, symptom interference, and cancer-related fatigue in cancer patients undergoing radiotherapy and chemotherapy. Methods A total of 336 cancer patients undergoing radiotherapy and chemotherapy in the First Affiliated Hospital of Hebei North University from October 2020 to October 2021 were selected by convenient sampling. The related data were collected by general condition questionnaire, cancer fatigue scale (CFS), Chinese version memory symptom assessment scale (MSAS-Ch), and stress resistance scale (CD-RICS). Results The scores of cancer-related fatigues, stress resistance, and symptom disturbance were 30.55 ±8.26, 62.14 ±14.04, and 1.11 ± 0.38, respectively. The level of stress resistance played an intermediary role in symptom interference and cancer-related fatigue, accounting for 26.26% of the total effect. The level of stress resistance had a regulatory effect between symptom interference and cancer-related fatigue (3 = 0.102, AR2=0.382, P < 0.05). Conclusion The level of stress resistance plays a mediating effect and regulation between symptom interference and cancer-related fatigue. Encouraging patients to strengthen the level of stress resistance, strengthen positive psychological construction, and weaken the level of symptom interference is helpful to reduce cancer-related fatigue. [ABSTRACT FROM AUTHOR]

Non-small cell lung cancer (NSCLC) is one of the malignant tumors with high morbidity and mortality worldwide. Ferroptosis is a new type of programmed cell death caused by abnormal accumulation of iron-dependent reactive oxygen species (ROS) leading to lipid peroxidation. It involves the balance between iron metabolism, lipid metabolism, oxygen free radical reaction and lipid peroxidation. Recent studies have found that ferroptosis is closely related to the occurrence and development of NSCLC. Due to the emergence of chemotherapy resistance and radiotherapy resistance in the treatment of NSCLC, there is an urgent need to develop new effective drugs and treatment strategies. Traditional Chinese medicine has unique advantages in the prevention and treatment of NSCLC due to its multi-targets and minimal side effects. In this review, we summarize the mechanism of ferroptosis in NSCLC, and discuss the research status of active ingredients of traditional Chinese medicine, single-herb traditional Chinese medicine and Chinese herbal compounds in the intervention of NSCLC through ferroptosis, in order to provide a new theoretical basis for the research of ferroptosis pathway and the prevention and treatment of NSCLC by targeted ferroptosis of traditional Chinese medicine. [ABSTRACT FROM AUTHOR]

Copyright of Chinese Journal of Cancer Biotherapy is the property of Editorial Office of Chinese Journal of Cancer Biotherapy and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Copyright of Chinese Journal of Cancer Biotherapy is the property of Editorial Office of Chinese Journal of Cancer Biotherapy and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Copyright of Journal of Clinical Nursing in Practice is the property of Journal of Clinical Nursing in Practice (Editorial Board, Shanghai Jiao Tong University Press) and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Liquid biopsy is gradually being applied in the clinical diagnosis and treatment of lung cancer. At present, with the development of metabolomics, more and more metabolic biomarkers are considered as potential sensitive markers reflecting the occurrence and development of tumors. This article summarizes the changes in the main metabolic pathways of lung cancer, including glucose metabolism, amino acid metabolism, lipid metabolism, sphingolipid metabolism, glycerophospholipid metabolism, and purine metabolism. Meanwhile, this article reviews the role of metabolic biomarkers in the early diagnosis of lung cancer, predicting disease progression, and evaluating the efficacy of chemotherapy and immunotherapy, aiming to provide effective biomarkers for tumor diagnosis and treatment. [ABSTRACT FROM AUTHOR]

For advanced non-small cell lung cancer (NSCLC) patients with negative driver gene mutations, chemotherapy has always been the standard treatment option, and immune checkpoint inhibitors (ICIs) provide other treatment option for these patients. At present, the first-line treatment can choose chemotherapy, anti-angiogenic drugs or immunotherapy. Although the initial treatment can achieve a certain clinical curative effect, disease progression or treatment failure is eventually unavoidable. The second-line and subsequent treatments have poor efficacy and more effective drugs are needed clinically. An expert panel of respiratory medicine, pathology and medical oncology organized by Expert Committee on Non-small Cell Lung Cancer of the Chinese Society of Clinical Oncology conducted an in-depth discussion on evidences of clinical studies for second-line treatment of NSCLC patients with negative driver gene mutations, aiming to provide guidances for Chinese clinicians in choosing second-line treatment for NSCLC patients with negative driver gene mutations. [ABSTRACT FROM AUTHOR]

Copyright of Chinese Journal of Cancer Biotherapy is the property of Editorial Office of Chinese Journal of Cancer Biotherapy and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

The subject in this study was a female professional painter who underwent bilateral mastectomy because of bilateral breast cancer, experienced postoperative wound scarring, and developed alopecia due to the side effects of chemotherapy, which caused the patient to lose body image confidence and the motivation to engage in artistic creativity. The patient had shed tears early in the intervention and complained of difficulties with body image adjustment due to her altered appearance. Mastectomy patients must not only undergo drug treatment but also adjust psychologically to body image changes to decrease negative emotions. This was the author's motivation for involvement in this case. The nursing period was from 23 September to 30 December 2021. Physical, mental, spiritual, social, and family data were collected using observations and interviews. These data were evaluated and the main problems were determined to be disturbed body image related to altered body perception post- surgery, alopecia caused by chemotherapy, impaired physical mobility due to upper limb mobility limitations post-surgery, and nausea due to chemotherapy. The patient was encouraged to paint again and to use artistic creativity to comfort herself. Moreover, she was guided to express her innermost thoughts to face the impact of her changes in appearance. In addition, a care consultation channel was provided to facilitate experience sharing with other breast cancer patients, thus assisting the patient to cope with the mental impact of her treatments and face subsequent cancer treatments with a more positive attitude. Art therapy embraces a diverse variety of methods, including drawing and music. Art therapy is a valuable tool that facilitates both physical and mental healing. Based on this experience, nurses should include patients' close relatives when performing art therapy to facilitate shared care to overcome difficulties. We hope this nursing experience provides a practical reference for nurses. [ABSTRACT FROM AUTHOR]

Copyright of Journal of Clinical Nursing in Practice is the property of Journal of Clinical Nursing in Practice (Editorial Board, Shanghai Jiao Tong University Press) and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Copyright of Practical Oncology Journal is the property of Journal of Practical Oncology Editorial Office and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Copyright of Practical Oncology Journal is the property of Journal of Practical Oncology Editorial Office and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Copyright of Science & Technology of Food Industry is the property of Science & Technology of Food Industry Editorial Office and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Chemotherapy-induced nausea and vomiting ( CINV) are the most common and distressing adverse drug reactions experienced by cancer patients undergoing chemotherapy. In order to provide more standardized, scientific, and rational treatment for CINV, by referring to domestic and foreign clinical guidelines and literature reports, members of the expert group of Traditional Chinese Medicine Group, Oncology Branch of Chongqing Medical Association take the syndrome differentiation and treatment of traditional Chinese medicine as the basic point, combined with the principles of evidence-based medicine, and form the Expert Consensus on Diagnosis and Treatment of Chemotherapy-Induced Nausea and Vomiting in Traditional Chinese Medicine and Western Medicine after repeated discussion and modification. This consensus elaborated on the diagnostic criteria and standardized treatment modes of traditional Chinese and Western medicine for chemotherapy-induced nausea and vomiting [ABSTRACT FROM AUTHOR]

Copyright of Journal of Clinical Nursing in Practice is the property of Journal of Clinical Nursing in Practice (Editorial Board, Shanghai Jiao Tong University Press) and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

This article describes the nursing experience of a nasopharyngeal cancer patient who is receiving concurrent chemotherapy and radiotherapy. The nursing period lasted from September 10 to November 27 in 2019. Patient data was collected through interactions, interviews, physical assessments, and evaluated with Gordon's 11 functional health patterns. The patient's health problems were identified as oral mucous membrane impairment, skin integrity impairment and feelings of powerlessness. Nursing care was applied to increase oral hygiene, wound care, and pain medication. Additionally, caring was provided with empathy, listening to the patient's needs, and encouraging positive thinking. Activities were suggested based on the patient's preferences; this increased her positive energy and made her feel she had more control over her life. Staff respected the patient's cultural differences, educated her on the treatment process and side effects, and provided individual, high-quality complete international medical care. [ABSTRACT FROM AUTHOR]

OBJECTIVE: To observe the effects of Yangzheng Touxie Qudu compound traditional Chinese medicine on the immune microenvironment in patients after triple negative breast cancer (TNBC) surgery, and to probe into the therapeutic regimen for the patients after TNBC surgery. METHODS: This study was a prospective randomized controlled trial (RCT), a total of 90 patients underwent TNBC surgery admitted into the hospital from Mar. 2019 to Feb. 2021 were selected to be divided into treatment group and control group via completely randomization method, with 45 cases in each group. The control group received adjuvant chemoradiotherapy, and the treatment group received adjuvant chemoradiotherapy+Yangzheng Touxie Qudu compound traditional Chinese medicine, 30 days as 1 treatment cycle and 4 cycles as the node for efficacy evaluation. Evaluation indicators included tumor markers [serum carcinoembryonic antigen ( CEA), carbohydrate ( CA) 125 and CA153 ], tumor immune microenvironment [ serum interleukin (IL) 6, IL-2, soluble interleukin-2 receptor (sIL-2R) and tumor necrosis factor α (TNF-α)], incidences and tolerability of adverse reactions of chemotherapy. RESULTS: A total of 5 patients in both groups met the exclusion criteria during treatment, including 3 cases in the treatment group and 2 cases in the control group, so that 42 cases in the treatment group and 43 cases in the control group were set as the actual research objects. After both groups had finished 4 cycles of treatment, the serum CEA, CA125 and CA153 levels decreased, and those of the treatment group were lower than the control group, with statistically significant differences (P<0. 05); the serum IL-6, IL-2, sIL-2R and TNF-α levels of both groups had been decreased, and those of the treatment group were lower than the control group, with statistically significant differences (P<0. 05). The severity degree of adverse reactions of chemotherapy in the treatment group was lower than that in the control group, with statistically significant difference (P<0. 05); the differences of incidences of myelosuppression, hepatorenal function impairment, gastrointestinal reaction and neurovirulence between two groups were not statistically significant (P>0. 05); there were no statistical significance in differences of recurrence rate and trasfer rate between two groups (P > 0. 05). CONCLUSIONS: The application of Yangzheng Touxie Qudu compound traditional Chinese medicine on patients receive chemoradiotherapy after TNBC surgery can promote anti-tumor effect, improve tumor immune microenvironment and reduce adverse reactions of chemotherapy. [ABSTRACT FROM AUTHOR]

Background and objective For resectable non-small cell lung cancer (NSCLC), the CheckMate-816 study demonstrated that neoadjuvant chemoimmunotherapy increased the rate of complete pathologic response (pCR) by 21.8% compared with chemotherapy alone and resulted in a significant benefit in event-free survival (EFS). This study aimed to investigate the safety and feasibility of this approach in the real world. Methods Clinical data from patients with NSCLC who underwent surgery after neoadjuvant chemoimmunotherapy or chemotherapy alone in two centers were analyzed retrospectively, and subgroup analyses were performed for the chemoimmunotherapy group according to treatment cycle. The primary study endpoints were EFS and major pathologic response (MPR), and the secondary study endpoints were pCR, overall survival (OS), treatment-related adverse events (TRA.Es), and surgery-related metrics. Results As of April 2023, 89 patients had been enrolled, including 54 in the chemoimmunotherapy group and 35 in the chemotherapy alone group. MPR was achieved in 31 (57.4%) and 5 (14.3%) patients in the chemoimmunotherapy group and chemotherapy alone group, respectively (OR=8.09, 95%CI: 2.72-24.04, P<0.001); pCR was achieved in 25 (46.3%) patients in the chemoimmunotherapy group and no patient in the chemotherapy alone group (P<0.001). The median follow-up time was 22.1 months. At 24 months, the EFS rates of the chemoimmunotherapy group and the chemotherapy alone group were 77.0% and 56.7%, respectively (P=0.026), and the OS rates were 87.1% and 67.7%, respectively (P=0.020). In the neoadjuvant chemoimmunotherapy group, there was no significant difference between the 1-2 cycles and 3-5 cycles groups in terms of operation time, intraoperative blood loss, and postoperative complications. Conclusion Neoadjuvant chemoimmunotherapy was more effective than chemotherapy alone and did not increase the risk associated with surgery. An increase in the number of cycles of neoadjuvant chemoimmunotherapy had no significant effect on the difficulty of surgery. [ABSTRACT FROM AUTHOR]

Copyright of Practical Oncology Journal is the property of Journal of Practical Oncology Editorial Office and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Objective.This study mainly explores the role of serum microRNA-200a (miR-200a) and microRNA-152 (miR-152) in gestational trophoblastic tumors (GTN) prognosis. Methods.One-hundred GTN chemotherapy patients who treated in our hospital were collected as the observation group, according to the efficacy of chemotherapy, patients were divided into the good prognosis group (80 cases) and the poor prognosis group (20 cases), 103 healthy women who underwent physical examination were collected as the control group. Real-time fluorescence quantitative PCR method was applied to detect the expression levels of miR-200a and miR-152 in serum. Results.The serum miR-200a expression level in the observation group was higher than that in the control group, while the miR-152 expression level was lower than that in the control group (P < 0.05). With the prolongation of chemotherapy time, the expression level of miR-200a in the serum of the good prognosis group and the poor prognosis group decreased sequentially, while the expression level of miR-152 increased sequentially (P < 0.05). The expression level of miR-200a in the serum of the poor prognosis group before and after chemotherapy were higher than that of the good prognosis group, while the expression level of miR-152 was lower than that of the good prognosis group (P < 0.05). There was a statistically significant difference in the International Federation of Obstetrics and Gynecology (FIGO) prognosis score and pre chemotherapy blood HCG levels between the group with good prognosis and the group with poor prognosis (P < 0.05). The AUC of predicting poor prognosis in GTN chemotherapy patients with serum miR-200a and miR-152 expression levels before chemotherapy alone and in combination were 0.793, 0.844, and 0.887, respectively. MiR-200a, miR-152, and FIGO prognosis scores7 are associated with poor prognosis in GTN chemotherapy patients (P < 0.05). Conclusion.High expression of miR-200a and low expression of miR-152 before chemotherapy may be associated with poor prognosis in GTN chemotherapy patients, which can provide reference for the evaluation of chemotherapy prognosis. [ABSTRACT FROM AUTHOR]

Objective: To investigate the relationship between serum P53 and wild-type p53 induced phosphatase 1 (Wip1) levels and chemotherapy efficacy and prognosis in patients with small cell lung cancer (SCLC). Methods: A total of 109 patients with SCLC (SCLC group) who were admitted to Qingdao Central Hospital Affiliated to Qingdao University from June 2015 to June 2017 and 95 healthy volunteers in outpatient physical examination were selected as the control group. All patients with SCLC received EP regimen (etoposide combined with cisplatin) chemotherapy for at least 2 cycles, serum P53 and Wip1 levels were detected before chemotherapy, and all patients were followed up for 5 years after discharge. Overall survival (OS) of patients with SCLC during follow-up was counted. The relationship between serum Wip1 and P53 levels and clinicopathological characteristics, chemotherapy efficacy and prognosis of patients with SCLC were analyzed. Results: The serum P53 level in the SCLC group was lower than that in the control group (P < 0.05) and the serum Wip1 expression was higher than that in the control group (P < 0.05) The serum P53 level in patients with extensive period clinical stage and distant metastasis were lower than that in patients with limited period clinical stage and no distant metastasis (P < 0.05), and the serum Wip1 expression was higher than that in patients with limited clinical stage and no distant metastasis (P < 0.05) The serum P53 level in the ineffective group was lower than that in the effective group (P < 0.05), and the serum Wip1 expression was higher than that in the effective group (P < 0.05) The 5-year OS survival rates of low level P53 group and high expression Wip1 group were lower than those of high level P53 group and low expression Wip1 group (P < 0.05) Multivariate Cox regression analysis showed that chemotherapy resistance, distant metastasis and high expression of Wip1 were risk factors for poor prognosis in patients with SCLC (P < 0.05) and high level of P53 was a protective factor (P < 0.05) Conclusion: The decrease of serum P53 level and the increase of Wip1 expression in patients with SCLC are related to poor chemotherapy efficacy and poor prognosis. Detection of serum P53 expression and Wip1 level is helpful to evaluate the chemotherapy efficacy and prognosis of SCLC. [ABSTRACT FROM AUTHOR]

Objective: To investigate the effects of Huachansu capsule combine with synchronous radiotherapy and chemotherapy on serum pain mediators and helper T cell (Th)1, Th2 related cytokines in patients with locally advanced esophageal squamous cell carcinoma. Methods: A total of 80 patients with locally advanced esophageal squamous cell carcinoma in Shuyang Hospital Affiliated to Xuzhou Medical University were selected from February 2018 to February 2020. According to the random number table,the patients were divided into control group(n=40, synchronous radiotherapy and chemotherapy) and study group(n=40, Huachansu capsule combined with synchronous radiotherapy and chemotherapy). The efficacy, pain status [visual analogue pain scale(VAS), 5-hydroxytryptamine(5-HT), prostaglandin E2 (PGE2), substance P (SP)], Th1, Th2 related cytokines and incidence of adverse reactions between the two groups were compared. The Kaplan-Meier product limit method was used to plot the 2-year survival curves of two groups, and the Log Rank test was used to compare the differences in survival data between the two groups. Results: The total clinical effective rate of the study group was higher than that of the control group (P<0.05). The VAS score, 5-HT, PGE2 and SP in the study group after treatment were lower than those in the control group(P<0.05). Th1 related cytokines: interleukin (IL)-2, interferon-γ (INF-γ) and tumor necrosis factor-α(TNF-α) in the study group after treatment were lower than those in the control group(P<0.05). Th2 related cytokines: IL-4, IL-10, and IL-13 were higher than those in the control group (P<0.05). There were no statistically significant difference in the incidence of adverse reactions between the two groups (P>0.05). The 2-year overall survival(OS) rate of the study group was 57.50%, significantly higher than 45.00% of the control group. The 2-year progression free survival (PFS) rate of the study group was 42.50%, significantly higher than 35.00% of the control group (all P<0.05). Conclusion: Huachansu capsule combine with synchronous radiotherapy and chemotherapy for locally advanced esophageal squamous cell carcinoma patients, further increase in clinical total effective rate, at the same time, it can also reduce the secretion of serum pain mediators, regulate the levels of Th1 and Th2 related cytokines, improved patient survival rate. [ABSTRACT FROM AUTHOR]

Copyright of Journal of Clinical Nursing in Practice is the property of Journal of Clinical Nursing in Practice (Editorial Board, Shanghai Jiao Tong University Press) and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Background and objective The SMARCA4 mutation has been shown to account for at least 10% of non-small cell lung cancer (NSCLC). In the present, conventional radiotherapy and targeted therapy are difficult to improve outcomes due to the highly aggressive and refractory nature of SMARCA4-deficient NSCLC (SMARCA4-DNSCLC) and the absence of sensitive site mutations for targeted drug therapy, and chemotherapy combined with or without immunotherapy is the main treatment. Effective SMARCA4-DNSCLC therapeutic options, however, are still debatable. Our study aimed to investigate the efficacy and prognosis of programmed cell death 1 (PD-1) immune checkpoint inhibitors (ICIs) in combination with chemotherapy and chemotherapy in patients with stage III-IV SMARCA4-DNSCLC. Methods 46 patients with stage III-IV SMARCA4-DNSCLC were divided into two groups based on their treatment regimen: the chemotherapy group and the PD-1 ICIs plus chemotherapy group, and their clinical data were retrospectively analyzed. Efficacy assessment and survival analysis were performed in both groups, and the influencing factors for prognosis were explored for patients with SMARCA4-DNSCLC. Results Male smokers are more likely to develop SMARCA4-DNSCLC. There was no significant difference in the objective response rate (76.5% vs 69.0%, P=0.836) between chemotherapy and the PD-1 ICIs plus chemotherapy or the disease control rate (100.0% vs 89.7%, P=0.286). The one-year overall survival rate in the group with PD-1 ICIs plus chemotherapy was 62.7%, and that of the chemotherapy group was 46.0%. The difference in median progression-free survival (PFS) between the PD-1 ICIs plus chemotherapy group and the chemotherapy group was statistically significant (9.3 mon vs 6.1 mon, P=0.048). The results of Cox regression analysis showed that treatment regimen and smoking history were independent influencing factors of PFS in patients with stage III-IV SMARCA4-DNSCLC, and family history was an individual influencing factor of overall survival in patients with stage III-IV SMARCA4-DNSCLC. Conclusion Treatment regimen may be a prognostic factor for patients with SMARCA4-DNSCLC, and patients with PD-1 ICIs plus chemotherapy may have a better prognosis. [ABSTRACT FROM AUTHOR]

The genomic instability may lead to an initiation of cancer in many organisms. Homologous recombination repair (HRR) is vital in maintaining cellular genomic stability. RADS1 associated protein 1 (RADS1AP1), which plays a crucial role in HRR and primarily participates in forming D-loop, was reported as an essential protein for maintaining cellular genomic stability. However, recent studies showed that RADS1AP1 was significantly overexpressed in various cancer types and correlated with poor prognosis. These results suggested that RADS1AP1 may play a significant pro-cancer effect in multiple cancers. The underlying mechanism is still unclear. Cancer stemness-maintaining effects of RADS1AP1 might be considered as the most reliable mechanism. Meanwhile, RADS1AP1 also promoted resistance to radiation therapy and chemotherapy in many cancers. Thus, researches focused on RADS1AP1, and its regulatory molecules may provide new targets for overcoming cancer progression and treatment resistance. Here, we reviewed the latest research on RADS1AP1 in cancers and summarized its differential expression and prognostic implications. In this review, we also outlined the potential mechanisms of its pro-cancer and drug resistance-promoting effects to provide several potential directions for further research. [ABSTRACT FROM AUTHOR]

Copyright of Journal of Clinical Nursing in Practice is the property of Journal of Clinical Nursing in Practice (Editorial Board, Shanghai Jiao Tong University Press) and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Copyright of Practical Oncology Journal is the property of Journal of Practical Oncology Editorial Office and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Copyright of Practical Oncology Journal is the property of Journal of Practical Oncology Editorial Office and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Colorectal cancer（CRC） is a global digestive tract cancer which ranks among the top three in terms of mortality and incidence worldwide and poses a significant threat to human health. Common colorectal cancer chemotherapy drugs have certain side effects, so people are actively seeking low side effects of natural products to combat CRC. In this study, the inhibitory mechanism of Agrocybe cylindracea polysaccharide（ACP） on colorectal cancer cell proliferation was explored through in vitro cell experiments. The results showed that ACP inhibited the proliferation of colorectal cancer cells（HCT-116, CT26） in a concentration-and time-dependent manner, but exhibiting no obvious toxicity to normal intestinal epithelial cells IEC-6. In addition, RNA-seq results indicated that ACP down-regulated the oxidative phosphorylation pathway. Further experiments showed that ACP led to ROS accumulation, mitochondrial membrane potential loss and dysfunction, thereby promoting HCT-116 cells apoptosis. Interestingly, NAC（N-acetyl-L-cysteine） could inhibit ACP-induced apoptosis by scavenging ROS. Overall, the experimental results demonstrated that ACP could induce apoptosis of HCT-116 cells through the ROS-mitochondrial dysfunction pathway, ultimately achieving the goal of inhibiting their proliferation. It provided new clues for the development of low sensitivity drugs for the treatment of colorectal cancer, and provided theoretical basis for the utilization of ACP. [ABSTRACT FROM AUTHOR]

Copyright of Journal of Clinical Nursing in Practice is the property of Journal of Clinical Nursing in Practice (Editorial Board, Shanghai Jiao Tong University Press) and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Background and objective The relationship between nutritional status and prognosis of cancer patients has emerged as a hotspot for research. The aim of this study is to explore the application value of the geriatric nutritional risk index (GNRI) in assessing the prognosis of elderly patients with non-small cell lung cancer (NSCLC), and establish a Nomogram to predict the prognosis of elderly patients with NSCLC. Methods The data of patients with NSCLC aged >65 years who were initially treated in the First Affiliated Hospital of Zhengzhou University from January 2016 to December 2019 were retrospectively analyzed. To determine the optimal cut-off value for GNRI, receiver operating characteristic (ROC) curve was constructed, and the patients were divided into high and low GNRI groups. Kaplan-Meier curve and Log-rank test were used to compare overall survival (OS) of the two groups. Univariate and multivariate Cox regression was used to analyze the risk factors for poor prognosis in elderly patients with NSCLC. Nomogram predicting survival in elderly patients with NSCLC was constructed and validated by using R software. Results Statistically significant differences in age, gender, body mass index (BMI), histological type, albumin, treatment methods, neutrophil to lymphocyte ratio (NLR), prognostic nutritional index (PNI), systemic immune-inflammation index (SII) and cytokeratin 19 fragment (CYFRA.21-1) were observed between the high and low GNRI groups (P<0.05). The Kaplan-Meier curve showed a shorter OS in the low-GNRI group. Multivariate Cox regression analysis showed that CYF^A21-1>3.3 ng/mL was an independent risk factor for the development of OS in patients with NSCLC, and GNRI>97.09 was a protective factor [hazard ratio (HR)=0.52, 95% confidence interval (CI): 0.34-0.79, P<0.05]. Patients in the stage IV had a 1.98-fold increased risk of death compared with patients in the stage I (95%CI: 1.02-3.86, P<0.05). The risk of death was 3.58 times higher in patients receiving chemotherapy alone compared with those receiving combination therapy (95%CI: 2.03-6.32, P<0.05). A Nomogram constructed on the basis of GNRI, which predicted the OS of elderly patients with NSCLC with a concordance index (C-index) of 0.70 (95%CI: 0.65-0.76), and the area under the curve (AUC) for 1 and 2-year survival rates to be 0.93 (95%CI: 0.87-0.98) and 0.72 (95%CI: 0.63-0.80), respectively, and the calibration curve has a good coincidence of prediction. Conclusion High GNRI scores are significantly associated with improved survival in elderly patients with NSCLC, and reliance on cut-off values may provide the appropriate timing for nutritional support. The Nomogram constructed in this study can be used as an effective tool to predict the survival rate of elderly patients with NSCLC, which has strong clinical practicability. [ABSTRACT FROM AUTHOR]

Simultaneous multiple primary tumors on the same side of the lung with Tropheryma whipplei (TW) infection are rare. We reviewed the clinical data, imaging manifestations, pathological results, diagnosis and treatment of a primary pulmonary mucinous adenocarcinoma (PPMA) patient with bronchial squamous cell papilloma (BSCP) and TW infection, and discussed our treatment experience. The patient mainly presented with chronic cough and sputum, and computed tomography (CT) showed inflammatory changes with multiple nodular shadows. Biopsy of the lower lobe of the right lung showed PPMA, and right lung sub-branchial nodules discovered during bronchoscope revealed BSCP. Metagenomics next generation sequencing (mNGS) of bronchoalveolar lavage fluid showed mixed infection of Streptococcus pneumoniae and TW with a poor anti-infective effect. No clear genetic mutation was detected, and the patient was treated with chemotherapy and regularly followed up. We should improve the awareness of multiple pulmonary pathologies during clinical practice, avoid missed diagnosis and misdiagnosis, and carry out comprehensive treatment after clarifying the diagnosis as soon as possible. [ABSTRACT FROM AUTHOR]

Background and objective The clinical feature, treatment and outcomes of the patients with endotracheal cancer after radical surgery for primary lung cancer are unclear. This article will provide a detailed explanation of the above issues by summarizing the relevant cases. Methods We retrospectively reviewed five patients in Guangdong Provincial People's Hospital and retrieved 9 cases from other literatures by searching PubMed. Results For five patients in out institute, 4 endotracheal cancers were considered as secondary to lung cancers. Radical stump resection (n=2), concurrent chemoradio-therapy (CCRT) (n=1), chemotherapy (n=1) and palliative care (n=1) were performed separately in 5 patients. The patient underwent CCRT achieved the longest progression-free survival of 29.5 months. For 9 patients retrieved from other studies, 8 endotracheal cancers were defined as metastases. Radiotherapy alone (n=4), CCRT (n=2), chemotherapy alone (n=2) or surgery (n=2) were performed separately in 10 lesions of 9 patients. 1 patient with radiotherapy alone and 1 patient with CCRT achieved complete response. Conclusion More attention should be paid to the abnormality of the trachea after surgery of lung cancer. CCRT may be a good choice for endotracheal cancers after primary lung cancer. [ABSTRACT FROM AUTHOR]

Background and objective The treatment and diagnosis of non-small cell lung cancer (NSCLC) is still a difficult problem in the medical community, and exploring the molecular mechanism of the occurrence and development of NSCLC is a hot topic of the current research. Long non-coding RNA (lncRNA) NORAD is highly expressed in a variety of cancer cells. It may be a molecular target that promotes NSCLC. The aim of this study was to investigate the impacts of lncRNA NORAD on the proliferation, apoptosis, and chemosensitivity of NSCLC by regulating zinc finger protein 217 (ZNF217) through miR-199a-3p. Methods Real-time quantitative polymerase chain reaction (qRT-PCR) method was applied to detect the expressions of NORAD, miR-199a-3p and ZNF217 genes in normal lung epithelial cells BEAS-2B, lung cancer H460 cells, and Cisplatin (DDP) resistant cell lines H460/DDP. H460/DDP cells were devided into control group, si-NC group, si-NORAD group, miR-NC group, miR-199a-3p mimic group, si-NORAD+inhibitor NC group and si-NORAD+miR-199a-3p inhibitor group. Cell proliferation, apoptosis, the expression of NORAD, miR-199a-3p and ZNF217 genes of cells in each group were detected and the expression levels of Ki-67, caspase-9 and ZNF217 proteins in different cells were also observed. The relationship between miR-199a-3p, NORAD and ZNF217 was vefified. Results Compared with BEAS-2B cells, the expressions of NORAD, ZNF217 mRNA were significantly increased in H460 and H460/DDP cells (P<0.05) but the expression of miR-199a-3p was significantly reduced (P<0.05). Compared with H460 cells, the expression of NORAD and ZNF217 mRNA in H460/DDP cells was significantly increased (P<0.05) and the expression of miR-199a-3p was significantly reduced (P<0.05). Compared with the control group and si-NC group, the proliferation rate, NORAD and ZNF217 mRNA expression, Ki-67 and ZNF217 protein expression of H460/DDP cells in the si-NORAD group were significantly reduced (P<0.05), but the apoptosis rate, miR-199a-3p expression and caspase-9 expression were significantly increased (P<0.05). Compared with the miR-NC group, the proliferation rate, NORAD and ZNF217 mRNA expression, Ki-67 and ZNF217 protein expression of H460/DDP cells in the miR-199a-3p mimic group were significantly reduced (P<0.05), but the apoptosis rate, miR-199a-3p expression and caspase-9 expression were significantly increased (P<0.05). Compared with the si-NORAD+inhibitor NC group, the proliferation rate, ZNF217 mRNA expression, Ki-67 and ZNF217 protein expression of H460/DDP cells in the si-NORAD+miR-199a-3p inhibitor group were significantly increased (P<0.05), the apoptosis rate, miR-199a-3p expression and caspase-9 expression were obviously increased reduced (P<0.05). Conclusion Down-regulating NORAD expression can enhance miR-199a-3p expression and inhibit ZNF217 expression, thereby inhibiting H460/DDP cell proliferation, promoting apoptosis and enhancing its DDP chemotherapy sensitivity. [ABSTRACT FROM AUTHOR]

Copyright of Chinese Journal of Cancer Biotherapy is the property of Editorial Office of Chinese Journal of Cancer Biotherapy and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

OBJECTIVE: To explore the effects of Aidi injection on the incidence and severity of myelosuppression in patients with gastric cancer during chemotherapy, so as to provide reference for rational drug use in clinic. METHODS: A total of 1 860 inpatients with gastric cancer who received chemotherapy admitted into the First Affiliated Hospital of Anhui Medical University from Jun. 2016 to Jan. 2022 were extracted to be divided into the Aidi group and control group by the method of propensity score matching 1 ∶ 1, with 410 patients in each group. The levels of leukocytes and platelets and its inhibitory rates before and after chemotherapy were retrospectively compared between two groups. Logistic regression was used to further analyze the influencing factors of myelosuppression and the effect of Aidi injection, the applicability of Aidi injection was analyzed by stratification. RESULTS: Two groups of patients all completed three cycles of standard chemotherapy. The rates of leukocyte inhibition and platelet inhibition were respectively 2. 44% ( 10 / 410), 8. 78% ( 36 / 410), 8. 78% ( 36 / 410) and 13. 41% ( 55 / 410), and the rates of platelet inhibition were respectively 0% (0 / 410), 4. 63%(19 / 410), 4. 88% (20 / 410) and 4. 88%(20 / 410); in the control group, the rates of leukocyte inhibition were respectively 9. 27% (38 / 410), 20. 98%(86 / 410), 21. 71% (89 / 410) and 27. 56% (113 / 410), and the rates of platelet inhibition were respectively 2. 20%(9 / 410), 3. 90% (16 / 410),5. 37% ( 22 / 410) and 5. 61% ( 23 / 410), with statistically significant differences ( P < 0. 05). After chemotherapy, the level of white blood cell count in the Aidi group was significantly higher than that in the control group. After the second and third chemotherapy, the level of platelet count in Aidi group was significantly higher than that in control group, with statistically significant differences (P<0. 05). Regression analysis showed that Aidi injection was an independent factor in reducing the rate of leukocyte and platelet inhibition ( P < 0. 01). Stratified analysis showed that Aidi injection had significant efficacy on patients with different characteristics. CONCLUSIONS: Aidi injection could reduce the incidence and severity of myelosuppression during chemotherapy in gastric cancer patients. [ABSTRACT FROM AUTHOR]

Background and objective Studies have shown that the incidence and severity of corona virus disease 2019 (COVID-19) in patients with lung cancer are higher than those in healthy people. At present, the main anti-tumor treatments for lung cancer include surgery, immunotherapy, chemotherapy, radiotherapy, targeted therapy and anti-angiogenesis therapy. While the effects of different anti-tumor treatments on the occurrence and severity of COVID-19 pneumonia are not uniform. Therefore, we aimed to describe clinical characteristics and antitumor therapy of patients with lung cancer and COVID-19 pneumonia, and examined risk factors for severity in this population. Methods From December 1, 2022 to February 15, 2023, a retrospective study was conducted in 217 patients diagnosed with COVID-19 and pathologically confirmed lung cancer in the Jinling Hospital. We collected data about patients' clinical features, antitumor treatment regimen within 6 months, and the diagnosis and treatment of COVID-19. Risk factors for occurrence and severity of COVID-19 pneumonia were identified by univariable and multivariable Logistic regression models. Results (1) Among the 217 patients included, 51 (23.5%) developed COVID-19 pneumonia, of which 42 (82.4%) were classified as medium and 9 (17.6%) were classified as severe; (2) Univariate and multivariate analysis revealed overweight (OR=2.405, 95%CI: 1.095-5.286) and intrapulmonary focal radiotherapy (OR=2.977, 95%CI: 1.071-8.274) are risk factors for increasing occurrence of COVID-19 pneumonia, while other therapies are not; (3) Chronic obstructive pulmonary disease (COPD) history (OR=7.600, 95%CI: 1.430-40.387) was more likely to develop severe pneumonia and anti-tumor therapies such as intrapulmonary focal radiotherapy, chemotherapy, targeted therapy and immunotherapy did not increase severity. Conclusion Intrapulmonary focal radiation therapy within 6 months increased the incidence of COVID-19 pneumonia, but did not increase the severity. However, there was no safety concern for chemotherapy, targeted therapy, surgery and immunotherapy. [ABSTRACT FROM AUTHOR]

Copyright of Journal of Clinical Nursing in Practice is the property of Journal of Clinical Nursing in Practice (Editorial Board, Shanghai Jiao Tong University Press) and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

With the development of precision medicine for lung cancer, targeted therapy has greatly improved the survival and prognosis of patients with advanced non-small cell lung cancer (NSCLC), but the occurrence of acquired drug resistance ultimately leads to patients with no targeted drugs available and no standard treatment options for this group of patients afterwards. The emergence of immune checkpoint inhibitors (ICIs) has revolutionized the treatment of advanced NSCLC. However, due to the unique features of NSCLC with epidermal growth factor receptor (EGFR) mutation, such as immunosuppressive tumor microenvironment (TME), single ICIs treatment has limited clinical benefits in NSCLC patients with EGFR mutation, and the combination of ICIs with chemotherapy and/or targeted therapies is the trend. This review further discusses potential subpopulations with EGFR mutations that may benefit from ICIs treatment, and analyzes how decisions can be made in the era of combined immunotherapy to maximize the efficacy of ICIs treatment in EGFR mutation targeted therapy for NSCLC patients with drug resistance, with the aim of achieving individualized treatment. [ABSTRACT FROM AUTHOR]